aesthetic outcomes and optimization of symmetry following mastectomy with reconstruction, concerns regarding its oncologic safety persist. [4] [5] [6] [7] [8] [9] These concerns are based on laboratory studies demonstrating that adipose-derived stem cells and adipose-derived growth factors can modulate the behavior of breast tumors in vitro and in animal models. [10] [11] [12] [13] [14] [15] [16] [17] [18] Also, laboratory studies have shown that adipose-derived stem cells modulate desmoplasia by elaborating extracellular matrix proteins, attenuate the antitumor immune response, and promote angiogenesis. 4, 5, 19, 20 A few retrospective clinical studies have suggested that fat transfer may increase the risk of locoregional recurrence after mastectomy for ductal carcinoma in situ or following partial mastectomy. [6] [7] [8] 21 Aside from a recent matched controlled study that shows fat transfer to be oncologically safe, 22 most clinical studies have been limited by inadequate power to detect small effects.
Recent guiding principles published by the American Society of Plastic Surgeons acknowledge that a limited body of evidence shows fat transfer following postmastectomy breast reconstruction to be oncologically safe. 23 These guiding principles, however, also acknowledge the need for additional high-quality studies. As such, the American Society of Plastic Surgeons clinical trials committee sought to establish whether adjunctive fat transfer is associated with a higher risk of recurrence in patients who have undergone mastectomy with reconstruction for invasive breast cancer. Our experimental design took into consideration the relatively low baseline rate of cancer recurrence, and the fact that although fat transfer is very popular currently, it gained prominence as a technique relatively recently. Moreover, we recognized the immediate need for information examining the impact of fat transfer on cancer recurrence given its popularity-something that a prospective trial could not provide. The design of this study improves on previous work, with more representative selection of controls, adjustment for duration of follow-up, and sufficient power to detect a doubling of breast cancer recurrence risk.
PATIENTS AND METHODS

Study Design
A case-cohort design was used. The casecohort approach allows for greater precision in the circumstance of a rare outcome and adjustment for different durations of follow-up.
Study Population
Patients were identified through the tumor registry or data warehouse of four sites: University of Chicago, M. D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the Siteman Cancer Center at Washington University School of Medicine in St. Louis. Institutional review board approval was obtained at each site. Eligible patients consisted of all women 21 years and older with incident invasive ductal carcinoma, stages I through III, who were diagnosed between January 1, 2006, and December 31, 2011, and treated with mastectomy and immediate breast reconstruction. We excluded men, women younger than 21 years, women with prior breast cancer, and women with stage IV or inflammatory breast cancer. We also excluded women who had delayed breast reconstruction to minimize heterogeneity in time intervals between diagnosis, treatment, and fat transfer. Only patients with invasive ductal carcinoma were included, so patients with ductal carcinoma in situ only, lobular carcinoma in situ only, sarcoma, invasive lobular carcinoma, or no cancer were excluded.
Identification of Cases and Controls
Cases consisted of all eligible patients who had experienced a recurrence (local, regional, or distant) during the study period (January 1, 2006, to December 31, 2011) as reported by each site's tumor registry or cancer data warehouse. The cohort was a 30 percent random sample of the control population, defined as patients who did not have a recurrence during the study period. Exposure to fat grafting was measured using medical record review in three sites and a prospectively maintained plastic surgery clinical database (at Memorial Sloan Kettering Cancer Center). The approach of Cai and Zeng was used for power and sample size considerations. 24 
Statistical Analyses
Fisher's exact tests were used to evaluate general association for categorical data. The Wilcoxon rank sum test (using Van der Waerden or normal scores) was used for two-group comparisons of continuous covariates. Cox proportional hazards regression modeling was used to explore the association of covariates of interest with time to recurrence. Time to recurrence was defined as the time from the date of diagnosis to the date of a local, regional, or distant cancer recurrence. Patients who reached the end of the study period, were lost to follow-up, or died without documented disease recurrence were considered censored. The covariates of interest were as follows: fat transfer (yes or no), age, tumor stage (I through III), smoking status (yes or no), body mass index, estrogen receptor status (positive or negative), progesterone receptor status (positive or negative), HER2/Neu amplification status (positive or negative), receipt of adjuvant chemotherapy (yes or no), receipt of neoadjuvant chemotherapy (yes or no), receipt of adjuvant radiation therapy (yes or no), and receipt of adjuvant endocrine therapy (yes or no).
We report both bivariate and multivariate estimated hazard ratios with 95 percent confidence intervals. The final multivariate models did not include progesterone receptor status because it was highly correlated with estrogen receptor status. They did not include adjuvant therapies because they were highly correlated with stage. Statistical analyses were performed using SAS (Version 9.3; SAS Institute, Inc., Cary, N.C.) and R.
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RESULTS
We identified 3271 eligible patients across the four institutions. The study sample (n = 1197) consisted of all recurrences during the study period (n = 225) and a 30 percent random sample of the study population (n = 972) ( Table 1) . Based on this sample size, power was calculated to be 76 percent against a relative risk of 2 and 86 percent against a relative risk of 2.22, when using a one-sided test with type I error of 5 percent.
The median age was 47 ± 10.1 years. The median body mass index was 26.5 ± 5.6 kg/m 2 . Detailed in Table 1 , almost half of the patients in the study sample had stage I disease, and most had estrogen receptor-positive and progesterone receptor-positive tumors. More than half received adjuvant chemotherapy, and approximately onequarter received radiation therapy, endocrine therapy, or neoadjuvant chemotherapy. Although 80 percent of patients underwent reconstruction with breast implants, the remainder underwent reconstruction with autologous flaps, or a combination of flap and implant. Fat transfer was performed in 64 patients (5 percent), including 28 at M. D. Anderson, 26 at Memorial Sloan Kettering, seven at Washington University, and three at the University of Chicago.
Two hundred twenty-five patients, or 6.9 percent of the entire study population, had a recurrence of breast cancer. Of these, 124 recurrences were distant (55 percent), 24 were regional (11 percent), and 77 were local (34 percent). Forty-eight patients (4 percent) died during the study period. In bivariate analyses of associations between individual covariates of interest and time to recurrence (Table 2) , patients who underwent fat transfer had an equivalent risk of cancer recurrence relative to those who did not (hazard ratio, 0.99; 95 percent CI, 0.56 to 1.7). Patients with HER2/Neu-positive tumors had a lower hazard of cancer recurrence than patients with HER2/ Neu-negative tumors (hazard ratio, 0.62; 95 percent CI, 0.42 to 0.91). Patients with estrogen 
DISCUSSION
Fat transfer was not associated with an increased probability of breast cancer recurrence in this multicenter case-cohort study. Although fat transfer to the breast has also been used in the context of reconstruction for partial mastectomy, 26 or as the sole technique of breast reconstruction following mastectomy, 27 we investigated fat transfer as an adjunctive technique to prosthetic or flap-based reconstruction. Our findings are primarily applicable for patients with stage I through III invasive ductal carcinomas treated with mastectomy and immediate breast reconstruction.
Although several epidemiologic studies report a link between obesity in postmenopausal women and breast cancer, [28] [29] [30] [31] and translational research studies report that mesenchymal cells or adipose-derived stem cells support the progression of existing tumors, 10, 15, 16, [32] [33] [34] [35] none shows that adipocytes form tumors de novo. 5 As an endocrine organ, white adipose tissue may promote breast cancer through the secretion of adipokines such as leptin, 36, 37 or insulin-like growth factor. 38 Furthermore, reduced levels of adiponectin in obese patients fosters a permissive environment for the pro-oncogenic properties of leptin. 37, 39 Adipose-derived stem cells offer another mechanism by which white adipose tissue can simulate breast cancer cells. The progression of breast cancer is impacted by stromal cells of mesenchymal and hematopoietic origin. 5 Under defined conditions, adipocytes 40 and their progenitors promote tumorigenesis in both in vivo and in vitro models. 41 When adipose-derived stem cells are exposed to tumor-conditioned media secreted by breast cancer cell lines, they tend to proliferate, differentiate into myofibroblasts, enhance tissue stiffness through altered extracellular matrix deposition, secrete proangiogenic factors, and exhibit attenuated adipogenic differentiation. 41 Adipose-derived stem cells preferentially contribute vascular and fibrovascular tumor-associated fibroblasts to the tumor stroma, and bone marrow-derived mesenchymal stem cells contribute fibroblast-specific proteins. 34 Co-culture of adipose-derived stem cells with breast cancer cells can also facilitate tumor metastases. 15, 42, 43 These important translational data speak to the potential consequences of using purified adipose-derived stem cell grafts in the presence of active cancer cells. They may lead to the identification of molecular markers to predict cancer recurrence after fat grafting 42 but do not necessarily translate directly to current clinical practice. Unlike immunocompromised nude mice receiving purified adiposederived stem cell cultures, 43 immunocompetent human patients typically receive fat grafts containing a variable but low (2 to 8 percent) fraction of adipose-derived stem cells. 44, 45 The absence of an association between fat transfer and recurrence risk reported here is consistent with experimental studies showing that white adipose tissue may stimulate active but not dormant breast cancers. Human adipose-derived stem cells significantly increase their malignant potential when co-cultured with active, but not dormant, breast cancer cells in vitro and in a xenogenic murine recipient in vivo model. 15 Under experimental conditions, invasive breast cancer cells alter the phenotype of adjacent mature Although an oncologically permissible environment for fat grafting may exist when residual disease is resected and appropriate adjuvant therapy administered, increased recurrence risk may exist when fat is transferred in the presence of residual breast tissue. [46] [47] [48] The European Institute of Oncology reported a locoregional recurrence rate of 0.4 percent per year following partial mastectomy among 2784 subjects. 49 However, a retrospective review of 143 partial mastectomy patients found that fat transfer was associated with a 2.07 percent per year increased rate of locoregional recurrence. 7 By contrast, and in support of our data, recurrence rates in mastectomy patients after fat transfer increased 1.38 percent per year, 7 versus 1.1 percent per year in a historical control group of 677 patients who did not receive fat transfer. 50 In the absence of a prospective trial, the authors of this multicenter retrospective review of 646 fat transfer patients recommended a cautious oncologic follow-up protocol. 7 Fat transfer may be associated with recurrence after ductal carcinoma in situ, which we did not include in our study population. In a matched cohort study of 321 patients, a significantly higher incidence of local and locoregional recurrence after fat transfer was found when analysis was limited to patients with in situ disease. 6 A subsequent study limited to 59 patients with in situ disease who received fat transfer, and a matched cohort of 118 who did not, revealed a higher rate of locoregional recurrence in the fat transfer group (hazard ratio, 4.5; 95 percent CI, 1.1 to 18.2). 8 Patients younger than 50 years, with high-grade neoplasia and a Ki-67 value greater than or equal to 14, were also associated with an increased rate of recurrence after fat transfer in this study.
In the retrospective series by Petit et al., fat transfer was performed in 108 patients with in situ disease, with a locoregional recurrence rate of 2.33 percent per year versus 1.44 percent per year in 405 patients with invasive carcinomas. 7 The molecular signature of the epithelial component of the tumor microenvironment that regulates extracellular matrix remodeling differs between ductal carcinoma in situ and invasive ductal carcinoma. 51 Moreover, subtypes of ductal carcinoma in situ can be differentiated by unique molecular signatures expressed by their fibroblasts and vascular and inflammatory stromal cells. 52, 53 Recognizing these differences, Petit and colleagues 8 postulated that with fewer genetic perturbations than invasive carcinomas, intraepithelial neoplasias may be more efficient at responding to the stromal signaling that leads to malignant degeneration. Recently, this group reanalyzed their ductal carcinoma in situ study population over a longer period, to increase the number of recurrence events evaluated. 26 Relative to controls, the recurrence rate was not higher in patients receiving fat transfer following mastectomy (p = 0.56). It was somewhat higher in patients grafted following partial mastectomy, but the difference was not statistically significant (p = 0.20). In addition, Gale and colleagues did not report an increased rate of recurrence following fat transfer in ductal carcinoma in situ patients. 54 Fat transfer in these patients, however, was restricted to patients with clear margins and was delayed for 54 months after resection. By contrast, Petit et al. waited a mean of 25 months and had positive or close margins in 42 percent of fat-transferred patients but only 20 percent of controls, and thus the increased risk of recurrence may have been related to margin status. 8 Gale et al. suggested that early fat transfer (≤2 years) after tumor resection may increase the impact of fat transfer on recurrence rates. 54 Kronowitz et al.-who also support the oncologic safety of fat transfer in their study-suggest that lumpectomy accompanied by intraoperative radiation therapy only may have also impacted recurrence rates in the study by Petit et al. 22 Evaluation of the oncologic safety of fat transfer to facilitate breast reconstruction is challenging because recurrence of local or regional breast cancer after mastectomy is a relatively rare outcome, 55 many years of follow-up are necessary to evaluate recurrence, 56, 57 and fat transfer has become common only recently. Thus, we used a retrospective case cohort approach. Our study was sufficiently powered to detect a risk ratio of 2 or greater, in terms of association between fat transfer and breast cancer recurrence. Moving forward, we intend to continue to study cancer recurrence rates after fat transfer with a larger sample size and longer follow-up. This will improve on the risk ratio of 2 used in this study, and will allow us to comment on the impact of other factors on recurrence such as volume transferred and fat transfer techniques used in a statistically meaningful way. Although a prospective, randomized, controlled trial would be favorable over a retrospective analysis, it would be impractical to ask patients to agree to a control arm of no treatment for contour deformities. Finding an alternative control arm, such as temporary fillers or tissue rearrangement, would also be challenging. A prospective cohort study would also be useful but would require a substantially larger sample size and would not produce evidence for 5 to 10 years. Finally, a study using existing large administrative or clinical data sets is not feasible because fat transfer does not yet have a unique billing code and is not routinely recorded in cancer registries. To address an urgent need for evidence on the safety of fat transfer to the breast, 58 we used a case-cohort study design, which is appropriate for assessing the probability of rare outcomes in a more timely fashion than a prospective cohort study.
The retrospective nature of this study is a limitation. In addition, we did not adjust for differences among fat transfer techniques because of a lack of consensus, nuanced technique differences not captured by retrospective review, and insufficient power to evaluate the impact of different fat transfer techniques on recurrence. Still, various methods of fat harvest and processing may affect adipocyte viability and stem cell fraction. [59] [60] [61] [62] Although optimization of the adipose-derived stem cell-rich stromal vascular fraction of lipoaspirate may favor improved graft retention, 45 it may also increase the risk of exposure of adipose-derived stem cells to occult, residual tumor stroma. 45 All patients were treated at high-volume cancer centers and likely had access to timely cancer treatment and appropriate administration of adjuvant therapy. 48, 63 Thus, these results assume guideline-concordant care and may not be generalizable to all breast cancer patients. In addition, some of these patients may have sought a cancer center for their initial therapy but eluded detection by the institutional tumor registry for recurrences treated elsewhere. We assessed only patients undergoing mastectomy and immediate reconstruction, a population that tends to be healthier, has greater economic resources, and has more favorable tumors than breast cancer patients overall. [64] [65] [66] Although we adjusted for some clinical variables, we did not adjust for health status or social factors. Future studies should include patients who have fat transfer after delayed reconstruction and after breast conservation therapy. As fat transfer to the breast becomes more common and acquires more indications, such studies ought to become more feasible.
CONCLUSIONS
Fat transfer was not associated with a higher probability of recurrence in this multisite population of local and regional breast cancer patients treated with mastectomy and reconstruction. Although the precision of the study was somewhat limited, it provides evidence that fat transfer does not increase the probability of invasive breast cancer recurrence by a factor of at least 2.0. Future studies of a larger sample of immediate reconstruction patients, and studies of fat transfer after delayed reconstruction or breast conservation therapy, are warranted.
